Table 1

Overview of the immune monitoring results

Peptide-specific immune responesSeptember 13, 2018 (V9)March 14, 2019 (V17)July 08, 2019 (post V18)
No.Peptide sequenceGene and somatic variantHLAVAF (%)CD4CD8CD4CD8CD4CD8
1HSYRGTGGIFKTBL1XR1
NM_024665
c.G1462A:p.E488K
HLA-A*03:0136++
SI: 4.3 (1.7%)
+
SI: 2.1 (0.6%)
Pool peptide 1+5
+++
SI: 7.3 (0.4%)
Pool peptide 1+5
++++
SI: 15.9 (6.5 %)
2MMFRNYQRKCHD4
NM_001273
c.G1705A:p.V569M
HLA-A*03:0138++
SI: 3.8 (1,8%)
+
SI: 3.2 (0.6 %)
3EVSAAHRAHYFDNMT3A
NM_022552.4
c.G2375A:p.R792H
HLA-A*26:0136+++
SI: 7.7 (1.1%)
(+) positive tendency+
SI: 2.2 (0.6%)
Pool peptide 3+7
++++
SI: 21.6 (1.8%)
Pool peptide 3+7
4DPTASVPSMKIAA1549
NM_001164665
c.G4753A:p.V1585M
HLA-B*35:0133+++
SI: 5.6 (4.3%)
++
SI: 3.7 (1.6%)
Pool peptide 4+6
++++
SI: 11.6 (0.5%)
Pool peptide 4+6
5HIPIIWATSYPIK3C2B
NM_002646
c.G1919A:p.R640H
HLA-A*26:0145++++
SI: 13.1 (6,6%)
+++
SI: 6.2 (2.9%)
Pool peptide 1+5
+++
SI: 7.3 (0.4%)
Pool peptide 1+5
++++
SI: 15.9 (6.5 %)
6VQRRAQGKLFKEL
NM_000420
c.A869T:p.E290V
HLA-B*15:0137+
SI: 2.1 (1.0%)
Pool peptide 4+6
++++
SI: 11.6 (0.5)
Pool peptide 4+6
7AFDDKTRLVWWC3
NM_015691
c.T662C:p.V221A
HLA-C*04:0133Pool peptide 3+7
++++
SI: 21.6 (1.8%)
Pool peptide 3+7
8TGVPQSRPHIPRTQPQPRNF43
NM_017763.4
c.C1742A:p.P581H
Class II36++++
SI: 39.3 (1.7%)
+
SI: 2.5 (0.7%)
++
SI: 4.1 (0.3 %)
9MFKGVASSQFLPKGTKTSETD2
NM_014159.6
c.G158A:p.R53Q
Class II38++++
SI: 37.5 (0.9%)
+++
SI: 9.5 (2.0%)
++++
SI: 35.9 (2.4%)
10DWNPHQDLHAQDRAHRISMARCA4
NM_001128844.1
c.A3555T:p.Q1185H
Class II33
  • HLA: human leukocyte antigen type, for which binding was predicted. VAF: variant allele frequency, detection frequency of the mutated allele. The observed frequencies could be influenced by tumor content and copy number variations and do not directly equal the proportion of the mutation in the tumor. SI: Stimulation Index, x-fold increase of polyfunctional reactive T cells (at least two of the markers CD154, IFN-γ, TNF and/or IL-2 positive) in the stimulated specimen compared to the according negative control specimen. Additional information: proportion (%) of reactive T cells (IFN-γ, TNF, IL-2 and/or CD154 positive) of the CD4+ or CD8+ T cell population after in vitro amplification. Does not directly equal the frequency of specific cells in vivo. +, lightly positive; ++, positive; +++, strongly positive; ++++, very strongly positive; IFN, interferon; TNF, tumor necrosis factor; IL, interleukin.